Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) CAS No. 68227-46-3

U. S. EPA HPV Challenge Program Submission

February 2003 Revised on June 30, 2003

Submitted by

PPG Industries, Inc. One PPG Place Pittsburgh, PA 15272

TEST PLAN

Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) CAS No. 68227-46-3

| ENDPOINT | Information Available (Yes/No) | Testing Required (Yes/No) | |
|---|--------------------------------------|---------------------------|--|
| Physical-chemical Data | | | |
| Melting Point | No | No | |
| Boiling Point | No | No | |
| Vapor Pressure | Yes* | No | |
| Water Solubility | No | Yes | |
| Partition Coefficient | Yes* | No | |
| Environmental Fate and Pathway | | | |
| Photodegradation | Yes* | No | |
| Stability in Water | Yes* | No | |
| Transport/distribution (Fugacity) | Yes* | No | |
| Biodegradation | No | Yes | |
| Ecotoxicity | | | |
| Acute Toxicity to Fish | No | No | |
| Acute Toxicity to Aquatic Invertebrates | No | Yes | |
| Acute Toxicity to Aquatic Plants | No | Yes | |
| Chronic Toxicity to Aquatic Invertebrates | No | Yes | |
| Toxicological Data | | | |
| Acute Toxicity | No | Yes | |
| Repeated Dose Toxicity | No | Yes** | |
| Repro/Developmental Toxicity | No | Yes** | |
| Genetic Toxicity <u>in vitro</u> (Gene Mutation) | No | Yes | |
| Genetic Toxicity <u>in vitro</u> (Chromosomal Aberration) | No | Yes | |

^{*}Calculated Data will be used.

^{**}A combined repeated dose/reproductive/developmental toxicity study will be conducted.

TABLE OF CONTENTS

| 1. | Sponsoring Companies | 4 |
|----|---|---|
| 2. | Test Substance | 4 |
| 3. | Criteria for Determining Adequacy of Data | 5 |
| 4. | Test Plan | |
| 4. | .1 Physical/Chemical Properties | 5 |
| 4. | .2 Environmental Fate/Pathways | |
| 4. | | |
| 4. | .4 Human Health Data | |
| | 4.4.1 Acute Mammalian Toxicity | 6 |
| | 4.4.2 Repeated Dose Mammalian Toxicity | 6 |
| | 4.4.3 Genetic Toxicity | |
| | 4.4.4 Reproductive/Developmental Toxicity | |
| 5. | Summary | |
| 6. | Appendix 1-Robust Summaries | |

1. Sponsoring Company

PPG Industries, Inc. is the manufacturer of Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) and is the sponsor of this substance for the U.S. Environmental Protection Agency's HPV Chemical Challenge Program.

2. Test substance

Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) is an isolated intermediate and subsequently used to produce a resin that is the component of paint products. This test substance is manufactured at one PPG production facility. The majority of this test substance (~70 to 85%) is currently used at that PPG location. Filled stainless steel semi-bulk tanks containing the test substance, as an isolated intermediate, are transported and stored at a warehouse for captive use on-site. The remaining small portion of the test substance is sold to two other companies, where it is also used as an intermediate that undergoes further reaction to form a resin. Filled lined steel drums are shipped via common carrier to the customers.

Since the test substance is an intermediate to be used for a production of resin and the vapor pressure is expected to be very low, the only reasonably anticipated potential exposure would be by skin contact and would occur in an occupational setting to a limited number of workers at PPG and customer sites. There would be no reasonably anticipated exposure to the general public.

The molecular structure of the test substance is as follows:

The test substance is produced commercially as 75% solids [Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1)] in the presence of Methyl Isobutyl Ketone (MIBK) solvent (2-3%), 2-butoxy ethanol (6-7%),

and water (15-17%). At this concentration in this solvent system, the test substance is a clear, light yellow, liquid. In order to prepare an isolated sample of the test substance (100% of CAS No 68227-46-3) for HPV testing, an attempt was made to drive off the solvents by distillation. However, this removal of excess solvents from the substance resulted in the formation of polymeric by-products. Therefore, it was not possible to prepare the isolated (solvent-free) test substance for HPV testing. Instead, the test substance was prepared in MIBK as usual and then diluted with water. The aqueous solution was then vacuum stripped to remove the MIBK and a portion of the water, resulting in a sample containing the test substance at 71% solids in water.

3. Criteria for Determining Adequacy of Data

All relevant data were reviewed and assessed for adequacy according to the standards of Klimisch *et al.* (1977). Four reliability categories, 1-reliable without restriction, 2-reliable with restriction, 3-not reliable, and 4-not assignable, have been established and a rating of 1 and 2 were considered to be adequate.

4. Test Plan

The Test Plan was developed using approaches that attempt to utilize minimum numbers of animals for testing while still meeting the data development requirements of the HPV program. A thorough data search was conducted using various available databases and company reports prior to development of the Test Plan. Additionally, consideration was given to possible use of Structure Activity Relationships or read-across comparison techniques based on a category approach. However, no relevant data were identified in either the published or unpublished literature. As detailed in the specific sections of the Test Plan below, the proposed studies incorporate the animal saving techniques recommended by EPA in their October 14, 1999 letter to HPV chemical sponsors.

4.1 Physical/Chemical Properties

No measured data are available for melting point, boiling point, vapor pressure, octanol/water partition coefficient, and water solubility. Because producing pure material (free of solvents) for the purposes of determining a melting point and a boiling point is not possible, no meaningful data can be generated. Therefore, no testing for melting and boiling points will be conducted.

Data for vapor pressure and partition coefficient (Kow) are estimated (calculated) using a modeled approach. The vapor pressure is estimated to be 2.62E-8 mm Hg and the partition coefficient (Log KOW) is estimated to be 4.38. These values will be revised when the measured water solubility is available. No testing for these end points will be conducted.

Since no data are available, measurement of water solubility will be performed.

4.2 Environmental Fate/Pathways

Data for photodegradation, stability in water, and environmental transport were estimated using the EPIWIN/HYDROWIN/AOPWIN program. The estimated photodegradation hydroxyl

radical rate constant was estimated to be 113.7966 E-12 cm³/molecule-sec with a half-life calculated to be 1.128 hours. Aqueous base/acid-catalyzed hydrolysis indicates that the estimated total Kb for pH >8 is 1.343 E+1 L/mol-sec with a half-life calculated to be 14.339 hours. Level III fugacity modeling indicates that the test substance should partition to water (14.4 %), air (3.23E-5 %), soil (79.1 %), and sediment (6.52 %). No data on biodegradability is available. In order to fulfill this end point, a ready biodegradability study (OECD Guideline 301) will be conducted.

4.3 Ecotoxicity

There were no reports or studies concerning the toxicity of the test substance to fish, aquatic invertebrates, or aquatic plants. In order to fulfill HPV toxicity testing requirements, an acute and chronic toxicity to aquatic invertebrates (OECD Guidelines 202 and 211), and an acute toxicity to algae (OECD Guideline 201) will be conducted.

In its guidance on data development for the HPV program, EPA recommends use of chronic toxicity testing in *Daphnia* (in place of acute toxicity testing in fish and *Daphnia*) and toxicity to plant (algae) for chemicals determined to have a Log Kow equal to or greater than 4.2. However, the EPA guidance further indicates that acute aquatic toxicity testing may be relevant for chemicals that are dispersible in water.

Since the estimated Log Kow value of this test substance is greater than 4.2 and the material would be somewhat dispersible, PPG will conduct the acute toxicity to *Daphnia* in addition to chronic toxicity to *Daphnia* and acute toxicity to algae. PPG will not conduct the acute fish toxicity test since the data from acute toxicity testing to *Daphnia* and algae would provide information on acute ecotoxicity. This proposed testing should provide sufficient information for the ecotoxicity end point.

4.4 Human Health Data

4.4.1 Acute Mammalian Toxicity

There were no reports or studies found that presented data on acute mammalian toxicity. In order to fulfill HPV toxicity testing requirements, one acute toxicity study (OECD Guideline 425, oral toxicity, up and down method) with a supplemental component of *in-vitro* cytotoxicity test will be conducted. The cytotoxicity test could provide useful information to estimate starting doses for *in-vivo* acute toxicity testing. This testing approach minimizes the number of animals used for testing to develop the needed information.

4.4.2 Repeated Dose Mammalian Toxicity

There were no reports or studies found that presented data on repeated dose mammalian toxicity. In order to fulfill HPV toxicity testing requirements, a combined repeated dose/reproductive/developmental toxicity screening study (OECD Guideline 422) will be conducted. This testing approach minimizes the number of animals used for testing to develop the needed information.

4.4.3 Genetic Toxicity

There were no reports or studies found that presented data on genetic toxicity. In order to fulfill HPV toxicity testing requirements, PPG will conduct two <u>in-vitro</u> genetic toxicity studies (OECD Guidelines 471 and 473).

4.4.4 Reproductive/Developmental Toxicity

There were no reports or studies found that presented data on reproductive/developmental toxicity. In order to fulfill HPV toxicity testing requirements, a combined repeated dose/reproductive/developmental toxicity screening study (OECD Guideline 422) will be conducted (see section 4.4.2). This testing approach minimizes the number of animals used for testing to develop the needed information.

5. Summary

A thorough data search was conducted using various databases and company reports. However, no existing published or unpublished data on the test substance were found. Estimated information derived from commonly used models is presented to satisfy most physical/chemical properties and environmental fate data end points. Additional studies recommended are water solubility and a biodegradation tests. No data are available on ecotoxicity or mammalian toxicity. Acute toxicity tests to aquatic invertebrates and algae and a chronic toxicity test to aquatic invertebrates will be conducted due to the high estimated Log Kow value. In order to minimize the number of animals needed to estimate the health effects end points, it is proposed that an up and down method will be used in the conduct of an acute oral toxicity study and that *in-vitro* methods are utilized for genetic toxicity. Additionally, a combined repeated dose/reproductive/developmental toxicity study (OECD Guideline 422) will be conducted in order to fulfill the repeated dose, reproductive, and developmental toxicity endpoints while minimizing the number of animals required.